Revolution Medicines reported that its drug daraxonrasib nearly doubled overall survival in a Phase 3 trial for advanced pancreatic cancer, targeting a mutation long considered impossible to drug.
Browsing: pancreatic cancer
Revolution Medicines reported that its drug daraxonrasib nearly doubled overall survival in a Phase 3 trial for advanced pancreatic cancer, targeting a mutation long considered impossible to drug.